Kyverna Therapeutics, Inc.
No SEC Form 4 filings for $KYTX in the last 30 days.
The article reviews CAR-T companies developing therapies for autoimmune diseases. Kyverna Therapeutics’ miv-cel (CD19) is in phase 3 for stiff person syndrome, with a rolling FDA BLA filing started in May and completion expected by year end. Cabaletta’s rese-cel (CD19) is in phase 1/2 for SLE and other indications, with June myositis results. Cartesian’s Descartes-08 (BCMA, mRNA) is in phase 3 for myasthenia gravis.
BlackRock, Inc. filed a Schedule 13G reporting a 5.1% beneficial stake in Kyverna Therapeutics (KYTX), totaling 3,103,757 shares. The filing shows sole voting power of 3,069,290 shares and sole dispositive power of 3,103,757 shares, with no shared voting or dispositive authority.
Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,
Over the past 7 days, alphai's AI scored 1 news story mentioning KYTX (Kyverna Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KYTX coverage spans financial news, corporate actions and sector analysis.
Near-term catalyst is regulatory filing progress and phase 3 read-through for autoimmune indications (stiff person syndrome, myasthenia gravis).
A new 5.1% beneficial stake by BlackRock can shift perceived institutional support and ownership dynamics, but it is not a control transaction.
The agreement resets Kyverna’s manufacturing and supply framework for miv-cel, including minimum order commitments and inflation-linked pricing.
Kyowa Kirin’s participation may improve predictability for U.S. facility readiness and related regulatory interactions.
The amendment changes Kyverna’s near-term financing optionality and the conditions under which additional Term B and Term C terms become effective, plus shifts when minimum revenue covenants start.
alphai scores every news story that mentions KYTX with an AI model for sentiment and relevance, and aggregates insider trades from Kyverna Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article reviews CAR-T companies developing therapies for autoimmune diseases. Kyverna Therapeutics’ miv-cel (CD19) is in phase 3 for stiff person syndrome, with a rolling FDA BLA filing started in May and completion expected by year end. Cabaletta’s rese-cel (CD19) is in phase 1/2 for SLE and other indications, with June myositis results. Cartesian’s Descartes-08 (BCMA, mRNA) is in phase 3 for myasthenia gravis.
7 min readBlackRock, Inc. filed a Schedule 13G reporting a 5.1% beneficial stake in Kyverna Therapeutics (KYTX), totaling 3,103,757 shares. The filing shows sole voting power of 3,069,290 shares and sole dispositive power of 3,103,757 shares, with no shared voting or dispositive authority.
2 min readKyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,
3 min readThe FDA outlined multiple initiatives to strengthen U.S. drug manufacturing and supply chain resilience, including its voluntary PreCheck Pilot Program, which on June 29, 2026 listed seven participating companies: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. It also described programs for faster clinical development, priority ANDA reviews, accelerated CNPV review, updated inspection compliance, and a proposed drug manufacturing registrati
6 min readKyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8 ,
4 min readKyverna Therapeutics (Nasdaq: KYTX) appointed Ritesh Srivastava as Chief Legal and Compliance Officer effective June 22, 2026, to support its transition toward commercialization of miv-cel (KYV-101). Srivastava joins from BPGbio and previously served at Spectrum Pharmaceuticals. The company also granted him an inducement option for 260,000 shares vesting over four years.
3 min readBloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.
6 min readKyverna Therapeutics reported that its Chief Financial Officer, Gregory S. Martini, was granted 325,000 stock options. These options have an exercise price of $8.54 per share and expire on May 18, 2036. The vesting schedule begins with one-quarter on May 18, 2027, with the remainder vesting monthly over the subsequent three years, contingent on his continuous service.
2 min readKyverna Therapeutics, Inc. has filed a Form 3 identifying Gregory S. Martini as a reporting person in his new role as Chief Financial Officer. This initial statement of beneficial ownership indicates that, as of this filing, Martini does not hold any beneficial ownership of securities, nor are there any reported share purchases, sales, or derivative positions. The filing serves to establish his insider status without detailing any transactions or holdings.
1 min readKyverna Therapeutics reported a first-quarter loss per share of 66 cents. This financial update is identified with the stock symbol KYTX.
2 min read
